Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Astegolimab for COPD Exacerbation Reduction
2022-502234-70-00Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 40
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Astegolimab arm with Placebo arm (2 arms). Primary endpoint: Annualized rate of moderate and severe COPD exacerbations over the 52-week treatment period. Started Jun 2023; status: completed.
02
Drugs
astegolimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2022-502234-70-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502234-70-00.